BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 18954041)

  • 21. Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma.
    Wu MS; Wang GF; Zhao ZQ; Liang Y; Wang HB; Wu MY; Min P; Chen LZ; Feng QS; Bei JX; Zeng YX; Yang D
    Mol Cancer Ther; 2013 Sep; 12(9):1728-37. PubMed ID: 23699656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of Potent SMAC Mimetics that Sensitize Cancer Cells to TNF Family-Induced Apoptosis.
    Welsh K; Milutinovic S; Ardecky RJ; Gonzalez-Lopez M; Ganji SR; Teriete P; Finlay D; Riedl S; Matsuzawa S; Pinilla C; Houghten R; Vuori K; Reed JC; Cosford ND
    PLoS One; 2016; 11(9):e0161952. PubMed ID: 27617834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fragment-based design of small molecule X-linked inhibitor of apoptosis protein inhibitors.
    Huang JW; Zhang Z; Wu B; Cellitti JF; Zhang X; Dahl R; Shiau CW; Welsh K; Emdadi A; Stebbins JL; Reed JC; Pellecchia M
    J Med Chem; 2008 Nov; 51(22):7111-8. PubMed ID: 18956862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 domains.
    Nikolovska-Coleska Z; Meagher JL; Jiang S; Kawamoto SA; Gao W; Yi H; Qin D; Roller PP; Stuckey JA; Wang S
    Anal Biochem; 2008 Mar; 374(1):87-98. PubMed ID: 18023397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A dimeric Smac/diablo peptide directly relieves caspase-3 inhibition by XIAP. Dynamic and cooperative regulation of XIAP by Smac/Diablo.
    Gao Z; Tian Y; Wang J; Yin Q; Wu H; Li YM; Jiang X
    J Biol Chem; 2007 Oct; 282(42):30718-27. PubMed ID: 17724022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual action Smac mimetics-zinc chelators as pro-apoptotic antitumoral agents.
    Manzoni L; Gornati D; Manzotti M; Cairati S; Bossi A; Arosio D; Lecis D; Seneci P
    Bioorg Med Chem Lett; 2016 Oct; 26(19):4613-4619. PubMed ID: 27578248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small-molecule SMAC mimetics as new cancer therapeutics.
    Bai L; Smith DC; Wang S
    Pharmacol Ther; 2014 Oct; 144(1):82-95. PubMed ID: 24841289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells.
    Sun H; Lu J; Liu L; Yang CY; Wang S
    ACS Chem Biol; 2014 Apr; 9(4):994-1002. PubMed ID: 24521431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis.
    Servida F; Lecis D; Scavullo C; Drago C; Seneci P; Carlo-Stella C; Manzoni L; Polli E; Lambertenghi Deliliers G; Delia D; Onida F
    Invest New Drugs; 2011 Dec; 29(6):1264-75. PubMed ID: 20614162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rational design, synthesis and characterization of potent, drug-like monomeric Smac mimetics as pro-apoptotic anticancer agents.
    Bianchi A; Ugazzi M; Ferrante L; Lecis D; Scavullo C; Mastrangelo E; Seneci P
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2204-8. PubMed ID: 22342627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.
    Nikolovska-Coleska Z; Xu L; Hu Z; Tomita Y; Li P; Roller PP; Wang R; Fang X; Guo R; Zhang M; Lippman ME; Yang D; Wang S
    J Med Chem; 2004 May; 47(10):2430-40. PubMed ID: 15115387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth.
    Ward GA; Lewis EJ; Ahn JS; Johnson CN; Lyons JF; Martins V; Munck JM; Rich SJ; Smyth T; Thompson NT; Williams PA; Wilsher NE; Wallis NG; Chessari G
    Mol Cancer Ther; 2018 Jul; 17(7):1381-1391. PubMed ID: 29695633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bivalent Smac mimetics with a diazabicyclic core as highly potent antagonists of XIAP and cIAP1/2 and novel anticancer agents.
    Peng Y; Sun H; Lu J; Liu L; Cai Q; Shen R; Yang CY; Yi H; Wang S
    J Med Chem; 2012 Jan; 55(1):106-14. PubMed ID: 22148838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs.
    Zobel K; Wang L; Varfolomeev E; Franklin MC; Elliott LO; Wallweber HJ; Okawa DC; Flygare JA; Vucic D; Fairbrother WJ; Deshayes K
    ACS Chem Biol; 2006 Sep; 1(8):525-33. PubMed ID: 17168540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Smac mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and Smac.
    Ramachandiran S; Cain J; Liao A; He Y; Guo X; Boise LH; Fu H; Ratner L; Khoury HJ; Bernal-Mizrachi L
    Leuk Res; 2012 Jun; 36(6):784-90. PubMed ID: 22325366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of novel second mitochondria-derived activator of caspase mimetics as selective inhibitor of apoptosis protein inhibitors.
    Wang J; Li W
    J Pharmacol Exp Ther; 2014 May; 349(2):319-29. PubMed ID: 24623800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib.
    Lecis D; Drago C; Manzoni L; Seneci P; Scolastico C; Mastrangelo E; Bolognesi M; Anichini A; Kashkar H; Walczak H; Delia D
    Br J Cancer; 2010 Jun; 102(12):1707-16. PubMed ID: 20461078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bivalent SMAC Mimetics for Treating Cancer by Antagonizing Inhibitor of Apoptosis Proteins.
    Zhu H; Li Y; Liu Y; Han B
    ChemMedChem; 2019 Dec; 14(23):1951-1962. PubMed ID: 31692274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP.
    Vucic D; Franklin MC; Wallweber HJ; Das K; Eckelman BP; Shin H; Elliott LO; Kadkhodayan S; Deshayes K; Salvesen GS; Fairbrother WJ
    Biochem J; 2005 Jan; 385(Pt 1):11-20. PubMed ID: 15485396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.